Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells

Denis Selimovic1, Benjamin B O W Porzig, Abdelouahid El-Khattouti

  • 1Institut National de la Santé et de la Recherche Médicale, U 977, France.

Cellular Signalling
|October 20, 2012
PubMed

Insights

Bortezomib induces apoptosis and autophagy in melanoma cells by activating endoplasmic reticulum stress and mitochondrial pathways. This study elucidates the molecular mechanisms behind bortezomib

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Endoplasmic reticulum (ER) stress and mitochondrial dysregulation are key targets for anticancer agents.
  • Bortezomib is a therapeutic agent with known anticancer properties.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which bortezomib induces apoptosis and autophagic formation in melanoma cells.
  • To investigate the roles of ER stress and mitochondrial pathways in bortezomib's effects.

Main Methods:

  • Treatment of melanoma cells with bortezomib.
  • Analysis of protein expression (Noxa, Mcl-1, HSP70, LC3).
  • Assessment of ER stress markers (intracellular Ca(2+) release) and mitochondrial pathways (ROS, AIF, cytochrome c).
  • Inhibition studies using caspase-3, ASK1, JNK, and HSP70 inhibitors.

Main Results:

  • Bortezomib induced apoptosis, ER stress, and autophagic formation in melanoma cells.
  • Key signaling pathways including IRE1α, ASK1, JNK, p38, and transcription factors were activated.
  • Mitochondrial dysregulation involved ROS accumulation, AIF and cytochrome c release, and caspase activation.
  • Inhibitor studies revealed distinct roles for caspase-3, ASK1, JNK, and HSP70 in modulating apoptosis and autophagy.

Conclusions:

  • Bortezomib triggers apoptosis and autophagic formation in melanoma cells through complex interplay of ER stress and mitochondrial dysregulation pathways.
  • The study provides novel insights into the molecular mechanisms of bortezomib action in melanoma.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...